Price T Rowe Associates Inc Spring Works Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 69,269 shares of SWTX stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,269
Previous 2,582,732
97.32%
Holding current value
$3.25 Million
Previous $114 Million
97.14%
% of portfolio
0.0%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding SWTX
# of Institutions
271Shares Held
72MCall Options Held
11.8MPut Options Held
1.27M-
Vanguard Group Inc Valley Forge, PA7.13MShares$335 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$264 Million0.0% of portfolio
-
Glazer Capital, LLC New York, NY4.11MShares$193 Million6.9% of portfolio
-
Fil LTD Hamilton, D03.01MShares$142 Million0.13% of portfolio
-
State Street Corp Boston, MA2.99MShares$141 Million0.01% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.93B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...